132 related articles for article (PubMed ID: 31755143)
1. Lactate dehydrogenase in dermatology practice.
Livesey A; Garty F; Shipman AR; Shipman KE
Clin Exp Dermatol; 2020 Jul; 45(5):539-543. PubMed ID: 31755143
[TBL] [Abstract][Full Text] [Related]
2. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma.
Deichmann M; Benner A; Bock M; Jäckel A; Uhl K; Waldmann V; Näher H
J Clin Oncol; 1999 Jun; 17(6):1891-6. PubMed ID: 10561230
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma.
Wang TS; Johnson TM; Cascade PN; Redman BG; Sondak VK; Schwartz JL
J Am Acad Dermatol; 2004 Sep; 51(3):399-405. PubMed ID: 15337983
[TBL] [Abstract][Full Text] [Related]
4. S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma.
Abusaif S; Jradi Z; Held L; Pflugfelder A; Weide B; Meier F; Garbe C; Eigentler TK
Melanoma Res; 2013 Oct; 23(5):396-401. PubMed ID: 23907232
[TBL] [Abstract][Full Text] [Related]
5. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse.
Egberts F; Hitschler WN; Weichenthal M; Hauschild A
Melanoma Res; 2009 Feb; 19(1):31-5. PubMed ID: 19104452
[TBL] [Abstract][Full Text] [Related]
6. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
[TBL] [Abstract][Full Text] [Related]
7. Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B.
de Lecea MV; Palomares T; Al Kassam D; Cavia M; Geh JLC; de Llano P; Muñiz P; Armesto D; Martinez-Indart L; Alonso-Varona A
J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):636-642. PubMed ID: 27633490
[TBL] [Abstract][Full Text] [Related]
8. Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase.
Deichmann M; Kahle B; Moser K; Wacker J; Wüst K
Br J Cancer; 2004 Aug; 91(4):699-702. PubMed ID: 15280926
[TBL] [Abstract][Full Text] [Related]
9. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
[TBL] [Abstract][Full Text] [Related]
10. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma.
Diem S; Kasenda B; Spain L; Martin-Liberal J; Marconcini R; Gore M; Larkin J
Br J Cancer; 2016 Feb; 114(3):256-61. PubMed ID: 26794281
[TBL] [Abstract][Full Text] [Related]
11. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
12. Serum S100B and LDH are not useful in predicting the sentinel node status in melanoma patients.
Egberts F; Momkvist A; Egberts JH; Kaehler KC; Hauschild A
Anticancer Res; 2010 May; 30(5):1799-805. PubMed ID: 20592382
[TBL] [Abstract][Full Text] [Related]
13. The revised American Joint Committee on Cancer staging system for melanoma.
Thompson JA
Semin Oncol; 2002 Aug; 29(4):361-9. PubMed ID: 12170439
[TBL] [Abstract][Full Text] [Related]
14. [Importance of LDH isoenzyme determination in monitoring the clinical course of malignant melanoma in the human].
Beyer C; Fiedler H; Wohlrab W; Zaumseil RP; Wittenbecher AE
Dermatol Monatsschr; 1984; 170(6):391-4. PubMed ID: 6468709
[No Abstract] [Full Text] [Related]
15. Aggressive behavior and elevated lactate dehydrogenase at baseline confer inferior prognosis in patients with primary cutaneous lymphoma.
Liu WP; Song YQ; Zheng W; Wang XP; Ding N; Zhu J
Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):534-40. PubMed ID: 23763922
[TBL] [Abstract][Full Text] [Related]
16. Targeting metabolic flexibility by simultaneously inhibiting respiratory complex I and lactate generation retards melanoma progression.
Chaube B; Malvi P; Singh SV; Mohammad N; Meena AS; Bhat MK
Oncotarget; 2015 Nov; 6(35):37281-99. PubMed ID: 26484566
[TBL] [Abstract][Full Text] [Related]
17. A new American Joint Committee on Cancer staging system for cutaneous melanoma.
Balch CM; Buzaid AC; Atkins MB; Cascinelli N; Coit DG; Fleming ID; Houghton A; Kirkwood JM; Mihm MF; Morton DL; Reintgen D; Ross MI; Sober A; Soong SJ; Thompson JA; Thompson JF; Gershenwald JE; McMasters KM
Cancer; 2000 Mar; 88(6):1484-91. PubMed ID: 10717634
[TBL] [Abstract][Full Text] [Related]
18. Importance of glycolysis and oxidative phosphorylation in advanced melanoma.
Ho J; de Moura MB; Lin Y; Vincent G; Thorne S; Duncan LM; Hui-Min L; Kirkwood JM; Becker D; Van Houten B; Moschos SJ
Mol Cancer; 2012 Oct; 11():76. PubMed ID: 23043612
[TBL] [Abstract][Full Text] [Related]
19. [The significance of changes in lactate dehydrogenase activity for the diagnosis and effective treatment of nephroblastoma in children].
Liubimova NV
Vopr Onkol; 1994; 40(7-12):319-22. PubMed ID: 7610628
[TBL] [Abstract][Full Text] [Related]
20. Metastatic volume: an old oncologic concept and a new prognostic factor for stage IV melanoma patients.
Panasiti V; Curzio M; Roberti V; Lieto P; Devirgiliis V; Gobbi S; Naspi A; Coppola R; Lopez T; di Meo N; Gatti A; Trevisan G; Londei P; Calvieri S
Dermatology; 2013; 227(1):55-61. PubMed ID: 24008289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
